Literature DB >> 25631772

Minimal residual disease-directed therapy in acute myeloid leukemia.

Sabine Kayser1, Richard F Schlenk2, David Grimwade3, Victor E D Yosuico4, Roland B Walter5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25631772     DOI： 10.1182/blood-2014-11-578815

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  16 in total

Review 1.  Frontline treatment of acute myeloid leukemia in adults.

Authors:  Gevorg Tamamyan; Tapan Kadia; Farhad Ravandi; Gautam Borthakur; Jorge Cortes; Elias Jabbour; Naval Daver; Maro Ohanian; Hagop Kantarjian; Marina Konopleva
Journal:  Crit Rev Oncol Hematol       Date:  2016-12-11       Impact factor: 6.312

2.  Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.

Authors:  E Manara; G Basso; M Zampini; B Buldini; C Tregnago; R Rondelli; R Masetti; V Bisio; M Frison; K Polato; G Cazzaniga; G Menna; F Fagioli; P Merli; A Biondi; A Pession; F Locatelli; M Pigazzi
Journal:  Leukemia       Date:  2016-06-28       Impact factor: 11.528

Review 3.  Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.

Authors:  Armin Rashidi; Roland B Walter; Martin S Tallman; Frederick R Appelbaum; John F DiPersio
Journal:  Blood       Date:  2016-06-27       Impact factor: 22.113

4.  Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach.

Authors:  Brian A Jonas; Bruno C Medeiros
Journal:  Oncology (Williston Park)       Date:  2016-04       Impact factor: 2.990

Review 5.  Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.

Authors:  Peter Hokland; Hans B Ommen; Matthew P Mulé; Christopher S Hourigan
Journal:  Semin Hematol       Date:  2015-04-07       Impact factor: 3.851

6.  Universal monitoring of minimal residual disease in acute myeloid leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Sheila Shurtleff; Allen Eng-Juh Yeoh; Wee Joo Chng; Siew Peng Chen; Jeffrey E Rubnitz; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  JCI Insight       Date:  2018-05-03

Review 7.  Targeting minimal residual disease: a path to cure?

Authors:  Marlise R Luskin; Mark A Murakami; Scott R Manalis; David M Weinstock
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

Review 8.  Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.

Authors:  Kristen Pettit; Wendy Stock; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2016-07

9.  Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.

Authors:  Juan Ouyang; Maitrayee Goswami; Jie Peng; Zhuang Zuo; Naval Daver; Gautam Borthakur; Guilin Tang; L Jeffrey Medeiros; Jeffrey L Jorgensen; Farhad Ravandi; Sa A Wang
Journal:  Am J Clin Pathol       Date:  2016-06-12       Impact factor: 2.493

10.  Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Authors:  Daisuke Araki; Brent L Wood; Megan Othus; Jerald P Radich; Anna B Halpern; Yi Zhou; Marco Mielcarek; Elihu H Estey; Frederick R Appelbaum; Roland B Walter
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.